Leap Therapeutics (NASDAQ:LPTX) Given New $5.50 Price Target at HC Wainwright

Leap Therapeutics (NASDAQ:LPTX - Get Free Report) had its price objective dropped by equities researchers at HC Wainwright from $7.00 to $5.50 in a note issued to investors on Tuesday, Benzinga reports. The firm currently has a "buy" rating on the stock. HC Wainwright's price target suggests a potential upside of 100.00% from the company's previous close.

Separately, Robert W. Baird cut their price target on shares of Leap Therapeutics from $11.00 to $9.00 and set an "outperform" rating for the company in a report on Tuesday, March 19th.

Leap Therapeutics Stock Performance

NASDAQ LPTX traded down $0.08 during mid-day trading on Tuesday, reaching $2.75. 247,938 shares of the stock were exchanged, compared to its average volume of 299,586. The company has a market capitalization of $70.40 million, a P/E ratio of -0.54 and a beta of 0.54. The business's 50 day moving average is $2.79 and its 200-day moving average is $2.85. Leap Therapeutics has a 1 year low of $1.24 and a 1 year high of $10.20.

Leap Therapeutics (NASDAQ:LPTX - Get Free Report) last posted its earnings results on Monday, March 18th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.56) by $0.10. Equities analysts predict that Leap Therapeutics will post -2.08 earnings per share for the current fiscal year.

Institutional Trading of Leap Therapeutics

Several large investors have recently bought and sold shares of the business. TD Asset Management Inc grew its position in shares of Leap Therapeutics by 100.0% in the third quarter. TD Asset Management Inc now owns 46,994 shares of the company's stock valued at $65,000 after purchasing an additional 23,497 shares in the last quarter. Key Client Fiduciary Advisors LLC increased its stake in shares of Leap Therapeutics by 43.3% in the 3rd quarter. Key Client Fiduciary Advisors LLC now owns 227,273 shares of the company's stock worth $314,000 after acquiring an additional 68,676 shares during the last quarter. Acuta Capital Partners LLC purchased a new position in shares of Leap Therapeutics during the 3rd quarter worth $489,000. 683 Capital Management LLC boosted its position in shares of Leap Therapeutics by 60.7% during the 3rd quarter. 683 Capital Management LLC now owns 490,000 shares of the company's stock valued at $676,000 after acquiring an additional 185,001 shares during the last quarter. Finally, Acadian Asset Management LLC grew its holdings in shares of Leap Therapeutics by 349.3% in the first quarter. Acadian Asset Management LLC now owns 282,413 shares of the company's stock valued at $750,000 after purchasing an additional 219,563 shares during the period. Hedge funds and other institutional investors own 30.46% of the company's stock.

About Leap Therapeutics

Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501.